



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

May 15, 2024

Christopher Downs  
Chief Financial Officer  
CNS Pharmaceuticals, Inc.  
2100 West Loop South, Suite 900  
Houston, TX 77027

**Re: CNS Pharmaceuticals, Inc.**  
**Registration Statement on Form S-3**  
**Filed May 9, 2024**  
**File No. 333-279285**

Dear Christopher Downs:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Lauren Hamill at 303-844-1008 with any questions.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc: Cavas Pavri